CM101 / TumorEnd - LARVOL DELTA

[PREPRINT] Preclinical Results: Canine Phase I Safety Study of CM-101, a Tumor Capillary Specific Streptococcal Polysaccharide Toxin, for application in Spontaneous Canine Cancer (bioRxiv) - "Total WBC (white blood cell) counts dropped below normal range two hours post-infusion, after 6-11 hours rising above the normal range, returning to baseline at 52 hours post-infusion. Creatinine kinase was elevated two hours post infusion returning to baseline in 6-72 hours. Urinalysis remained within normal limits."

Preclinical • Preprint • Oncology • Solid Tumor

[VIRTUAL] CM-101 A NOVEL CCL24 BLOCKING MONOCLONAL ANTIBODY DEMONSTRATES SAFETY, TARGET ENGAGEMENT AND LONG HALF- LIFE IN A PHASE 1 RANDOMIZED, CONTROLLED SINGLE ASCENDING DOSE TRIAL USING IV AND SC FORMULATIONS IN HEALTHY SUBJECTS (AASLD 2020) - "CM-101 as a single IV or SC dose up to 10 mg/kg was safe and well tolerated in healthy subjects, with a favorable PK profile supporting Q2W or Q3W dosing. Available formulations allow for home treatment (SC) as well as clinic-based treatment (IV). CM-101 efficiently binds CCL24 and neutralize its activity through CCR3."

Clinical • P1 data • Addiction (Opioid and Alcohol) • Fibrosis • Hepatology • Immunology • Inflammation • Liver Cirrhosis • Liver Failure • Non-alcoholic Fatty Liver Disease • Non-alcoholic Steatohepatitis • Pain • CCL4

[VIRTUAL] CM-101 DEMONSTRATES REDUCTION IN SERUM FIBROTIC BIOMARKERS IN A PHASE 1b RANDOMIZED, CONTROLLED MULTIPLE DOSE TRIAL IN NAFLD PATIENTS (AASLD 2020) - "12 weeks treatment with CM-101 was safe and well tolerated. Although low disease burden patients recruited, repeated CM-101 administration showed early signals of anti-fibrotic activity by serum biomarkers and elastography. These advantages support CM-101 anti-fibrotic activity mediated by CCL24 blockage."

Biomarker • Clinical • Late-breaking abstract • P1 data • Fibrosis • Hepatology • Immunology • Inflammation • Liver Cirrhosis • Meningioma • Non-alcoholic Fatty Liver Disease • Non-alcoholic Steatohepatitis • Oncology • Solid Tumor • CCL4 • TIMP1

CM-101 in PSC Patients -The SPRING Study (clinicaltrials.gov) - P2a; N=45; Recruiting; Sponsor: ChemomAb Ltd.

Clinical • New P2a trial • Hepatology

[VIRTUAL] CCL24 modulates fibrosis development in primary sclerosing cholangitis: correlation of human serum CCL24 levels with fibrosis markers and data from the Mdr2-/- mouse model. (EASL-ILC-I 2020) - "CCL24 expression correlates with increased expression of TIMP-1 and ELF scoring in the serum of PSC patients. CCL24 blockade using CM-101(D8), a specific anti-CCL24 antibody, in an animal model of cholestasis, reduced TIMP-1 and Col1a1 expression in the liver reflecting significant attenuation of hepatic fibrosis. These findings support the potential of CCL24 as a therapeutic target in liver fibrotic diseases and the anti-fibrotic activity of CM-101."

Cholestasis • Fibrosis • Hepatology • Immunology • Liver Cirrhosis • Liver Failure • Non-alcoholic Steatohepatitis • CCL4 • COL1A1 • TIMP1

Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and is Measurable with Collagen-Targeted Molecular MRI. (PubMed, Clin Cancer Res) - "In humans, post-chemoradiation tumor fibrosis is associated with OS and DFS. In mice, our MR findings indicate that translation of collagen molecular MRI with CM-101 to humans might provide a novel imaging technique to monitor fibrotic response to therapy in order to assist with prognostication and disease management."

Clinical • Journal • Fibrosis • Gastrointestinal Cancer • Immunology • Oncology • Pancreatic Cancer • Solid Tumor • MRI